TVTX Travere Therapeutics

• None no insider bought on the open market
• None no sales outside a trading plan
• $106M sold by 11 insiders under 10b5-1 plans

1. Insider
   Trade
   Value
   Traded, filed
2. Eric M Dube CEO
   Planned sale
   $13.1M 243,735 shares at $53.82 36% of stake
   Traded Oct 15 Filed Oct 19
   ↗
3. Christopher R. Cline CFO
   Planned sale
   $3.1M 50,508 shares at $62.34 37% of stake
   Traded Sep 15 Filed Sep 17
   ↗
4. Jula Inrig EVP, Head of R&D & CMO
   Planned sale
   $2.8M 44,674 shares at $62.34 31% of stake
   Traded Sep 15 Filed Sep 17
   ↗
5. Sandra Calvin SVP, Chief Accounting Officer
   Planned sale
   $335K 5,375 shares at $62.33 11% of stake
   Traded Sep 15 Filed Sep 17
   ↗
6. Peter Heerma EVP, Chief Commercial Officer
   Planned sale
   $17.9M 283,189 shares at $63.06 71% of stake
   Traded Sep 15–17 Filed Sep 17
   ↗
7. Eric M Dube CEO
   Planned sale
   $25.4M 400,000 shares at $63.48 48% of stake
   Traded Sep 15–17 Filed Sep 17
   ↗
8. William E. Rote Chief Research Officer
   Planned sale
   $13.1M 209,048 shares at $62.83 68% of stake
   Traded Sep 15–16 Filed Sep 17
   ↗
9. Elizabeth E Reed Chief Legal Officer and GC
   Planned sale
   $2.3M 37,500 shares at $62.34 26% of stake
   Traded Sep 15 Filed Sep 17
   ↗
10. Jeffrey A Meckler Director
    Planned sale
    $1.3M 20,000 shares at $67.31 18% of stake
    Traded Sep 10 Filed Sep 11
    ↗
11. Gary A Lyons Director
    Planned sale
    $633K 10,000 shares at $63.28 14% of stake
    Traded Aug 17–18 Filed Aug 19
    ↗
12. Roy D. Baynes Director
    Planned sale
    $225K 4,500 shares at $50.00 9.8% of stake
    Traded Jun 12 Filed Jun 16
    ↗
13. Timothy Coughlin Director
    Planned sale
    $501K 10,000 shares at $50.07 15% of stake
    Traded Jun 12 Filed Jun 16
    ↗
14. Timothy Coughlin Director
    Planned sale
    $141K 3,250 shares at $43.49 5.9% of stake
    Traded May 15 Filed May 19
    ↗
15. Jula Inrig Chief Medical Officer
    Planned sale
    $900K 20,000 shares at $45.00 15% of stake
    Traded May 4 Filed May 6
    ↗
16. Roy D. Baynes Director
    Planned sale
    $210K 4,500 shares at $46.65 11% of stake
    Traded May 5 Filed May 6
    ↗

Also filed in the last 12 months, not counted as buying or selling: 73 option exercises, 40 sales to cover taxes, 22 stock grants, and 2 gifts.